91´óÉñ

Clinical Trial</h3>\r\n<p><b>Offered by:</b> 91´óÉñ Children's Health, Jacksonville<br>\r\n<b>Location:</b> Jacksonville, Florida</p>\r\n<h3>Trial Name</h3>\r\n<p>SCUSF 0901 Phase II Placebo-Controlled Trial of Modafinil to Improve Neurocognitive Deficits in Children Treated for a Primary Brain Tumor</p>\r\n<p>&nbsp;</p>\r\n<h3>What is the trial about?</h3>\r\n<p>To compare the effects of Modafinil given to children with neurocognitive changes following treatment for brain cancer.</p>\r\n<h3>Who can participate?</h3>\r\n<p>Age ≥6 years and ≤17 years 10 months at the time of study entry.</p>\r\n<h3>What is involved?</h3>\r\n<p>Length of study is 10 weeks. Includes neurocognitive tests and physical exam.</p>\r\n"}} id=text-280e0fbc91 class=cmp-text>

Clinical Trial

Offered by: 91´óÉñ Children's Health, Jacksonville
Location: Jacksonville, Florida

Trial Name

SCUSF 0901 Phase II Placebo-Controlled Trial of Modafinil to Improve Neurocognitive Deficits in Children Treated for a Primary Brain Tumor

Ìý

What is the trial about?

To compare the effects of Modafinil given to children with neurocognitive changes following treatment for brain cancer.

Who can participate?

Age ≥6 years and ≤17 years 10 months at the time of study entry.

What is involved?

Length of study is 10 weeks. Includes neurocognitive tests and physical exam.

<strong>Trial Name: </strong>SCUSF 0901 Phase II Placebo-Controlled Trial of Modafinil to Improve Neurocognitive Deficits in Children Treated for a Primary Brain Tumor</p>\r\n<p><strong>IRB#</strong> 285283</p>\r\n"}} id=text-bb7597b482 class=cmp-text>

Trial Name: SCUSF 0901 Phase II Placebo-Controlled Trial of Modafinil to Improve Neurocognitive Deficits in Children Treated for a Primary Brain Tumor

IRB# 285283